Abstract
Introduction

Well known as an anticoagulant, pharmaceutical standard heparin is derived from natural animal sources such as pig intestine and beef lung. Originally from dog liver, heparin was discovered by McLean in 1916 and the term heparin was coined by Howell in 1918. The story of heparin discovery was fascinating considering McLean previously set out to look for natural procoagulant phosphatides [1]. Both McLean's heparphosphatide and Howell's heparin differ from today's heparin, but their discovery changed the classical viewpoint that anticoagulant in the body is protein based. Up to now, diverse new properties of heparin have been elucidated. The potential role of heparin in normal physiologic and pathophysical processes is analyzed in this review.
Effects of heparin beyond anticoagulant
Heparin used today is a mixture of water-soluble, highly sulphated and linear polysaccharides. As a member of the glycosaminoglycan family, heparin is mainly composed of repeating, variably-sulphated disaccharide units containing iduronic acid 2-sulphate, glucosamine 2, 6-disulphate and non-sulphated glucuronic acid. The specific pentasaccharide sequence of heparin contributes to its electrostatic interaction with antithrombin (AT), which then inactivates thrombin and other proteases involved in blood clotting
. Heparin remains the most important antithrombotic therapeutic drug until now. Actually, only onethird of heparin molecules contain pentasaccharide sequences with high affinity for AT [3] . The functional versatility and other therapeutic potential (Table 1) have been ascribed to heparin beyond its role as an anticoagulant [4] . Anti-inflammatory effects of heparin have been described frequently. Heparin has been shown to benefit patients with allergic inflammation, bronchial asthma and ulcerative colitis [5] . After the asthma patients inhaled aerosolized heparin, no change is detected in the level of coagulation. Heparin proved to be more effective than cromolyn sodium [6] . As the classic anticoagulant of choice to treat cancer patients with thrombosis, heparin also can improve cancer survival rates independently of the effect on thromboembolism. Heparin mainly prevents the metastatic cascade, which is responsible for most cancer-related deaths. Chemically modified heparins with no or limited anticoagulant activity also showed anti-metastatic properties [7] . LHD, one orally absorbable heparin derivative dramatically attenuated metastasis experimentally induced by murine melanoma or human lung carcinoma cells. Furthermore, it prevented tumour growth in secondary organs [8] . [9] . Recently, methods have been described to prepare structureoptimized heparin derivatives to increase selectivity [10] . [11] . LMWH may have several advantages over unfractionated heparin: it has a more predictable anticoagulant effect with, requires no monitoring of anticoagulation and has a lower incidence of heparin-induced thrombocytopenia (HIT) [12] . [17] . [32] . [35] . [52] with more precise structure so as to achieve high functional selectivity. In the coming years of the glycomics era, continuing efforts on in heparanome research [53] will likely lead to novel molecular therapeutic approaches for combating health problems.
Non-anticoagulant heparins
Cells adhere to communicate
Anti-adhesion activity of heparin
Anti-adhesion activity appears as a common mechanism of nonanticoagulant effects of heparins. During inflammatory responses,
Heparin binds to messengers in cell communication
As reviewed [33], heparin has been shown to bind to a variety of biologically important proteins including enzymes, growth factors, extracellular matrix (ECM) proteins and the cell surface proteins of pathogens (Table 2). The activities of these proteins are regulated by heparin, when electrostatic forces between the positively charged amino acids and the polyanionic groups in the glycosaminoglycan chain effect changes in protein conformations. The cytokines, as first messengers, form a complex network of immune competent cells communication [34]. Heparin inhibits cytokines that may contribute to angiogenesis, in which the fibroblast growth factor (FGF) cytokine family is among the best understood. Both heparin and LMWH have been shown to inhibit FGF-induced angiogenesis in a human in vitro angiogenesis model
